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 1. Introduction 
 Synthetic drug carriers that exploit natural cellular trans-
port pathways are highly desirable for diagnostic and thera-
peutic applications. [ 1 , 2 ] Of particular interest are carriers that 
resemble viruses and their ability to target and be internal-
ized by cells, but which are not infective or toxic. Features 
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of viruses important in their cellular traffi cking are their 
size (50–150 nm range) and their functional surface ligands, 
especially for cellular and sub-cellular receptors. It is not 
surprising therefore that many synthetic drug delivery sys-
tems have been based on virus-inspired designs. [ 3 , 4 ] These 
typically involve a therapeutic compound incorporated into a 
nanoscale carrier ‘core’, which is coated with ligand(s) aimed 
to specifi cally guide the carrier towards a particular cellular 
pathway, enabling delivery of the incorporated therapeutic 
to a desired location. [ 5 ] However, the carrier may not adopt 
the assumed ligand-directed pathway, as demonstrated by 
a recent landmark paper, [ 6 ] which indicated that some traf-
fi cking pathways can be perturbed by synthetic nanoparticles 
in ways that differ from the transport activated by the viral or 
bacterial ligand functionality alone. 
 Here we set out to probe if a ligand-mediated pathway, 
well-characterized for transport of molecules into and 
through the epithelial cells of the gut, could be exploited 
by model nanoparticle drug carriers for potential systemic 
delivery of biotherapeutics via mucosal surfaces. As the 
bioconjugate ligand we selected vitamin B 12 , as its intestinal  DOI: 10.1002/smll.201202623 
 The understanding and control of nanoparticle transport into and through cellular 
compartments is central to biomedical applications of nanotechnology. Here, it is 
shown that the transport pathway of 50 nm polystyrene nanoparticles decorated 
with vitamin B 12 in epithelial cells is different compared to both soluble B 12 ligand 
and unmodifi ed nanoparticles, and this is not attributable to B 12 recognition 
alone. Importantly, the study indicates that vitamin B 12 -conjugated nanoparticles 
circumnavigate the lysosomal compartment, the destination of soluble vitamin B 12 
ligand. Whereas cellular traffi cking of soluble B 12 is confi rmed to occur via the 
clathrin-mediated pathway, transport of B 12 -conjugated nanoparticles appears to 
predominantly take place by a route that is perturbed by caveolae-specifi c inhibitors. 
This data suggests that, following its conjugation to nanoparticles, in addition 
to dramatically increasing the cellular uptake of nanoparticles, the normal cell 
traffi cking of B 12 is switched to an alternative pathway, omitting the lysosomal stage: 
a result with important implications for oral delivery of nanoparticulate diagnostics 
and therapeutics. 
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uptake has already been considered for oral delivery of bio-
therapeutics. [ 7–10 ] Although previous attempts to deliver bio-
therapeutics directly conjugated to vitamin B 12 have resulted 
in loss of therapeutic activity due to digestion of the labile 
biotherapeutic in the gastrointestinal tract, [ 11 , 12 ] more recent 
studies have evaluated vitamin B 12 -conjugated nanoparticu-
lates as carriers with the potential to incorporate and protect 
the biotherapeutic. [ 10 , 13 ] 
 Importantly however, the use of B 12 -conjugated nanocar-
riers to deliver biotherapeutics across the intestinal surface 
assumes that the B 12 -nanoparticles traverse the epithelium 
in a manner that follows the soluble vitamin B 12 pathway, 
i.e. the attached nanoparticle does not perturb the biological 
transport pathway. This would involve cellular internalization 
of the entire cubilin receptor-intrinsic factor-B 12 -nanoparticle 
complex bound to megalin receptor via clathrin-coated vesi-
cles, [ 14 , 15 ] followed by an endosomal stage where the cubilin 
and megalin receptors dissociate from the complex and recycle 
to the epithelial cell surface. The remaining intrinsic factor 
(IF)-B 12 -nanoparticle complex would then be transported to 
the lysosome (where, in the case of soluble B 12 , IF protein 
is degraded to release free B 12 ) . 
[ 16 ] The vitamin B 12 -bearing 
nanoparticles would then be transported out of the lysosome, 
as B 12 is assumed to do by a yet unidentifi ed mechanism. 
[ 17 ] 
Of key signifi cance is that studies on the mechanism of cel-
lular internalization and intracellular traffi cking of B 12 -conju-
gated nanoparticles have not been reported previously in the 
literature. 
 Our aim, therefore, was to probe the mechanisms of 
entry and transport across the cells of nanoparticles conju-
gated to vitamin B 12 , and so demonstrate a model system 
that might have wider implications for delivery of thera-
peutic and/or diagnostic nanoparticles in general. [ 18–20 ] The 
model carrier was prepared from functionalized polysty-
rene (PS) nanoparticles spanning the 50–200 nm size range, 
covering viral dimensions and those reported optimal for 
endocytotic processes. [ 21 ] Nanoparticle surface decoration 
with the vitamin B 12 ligand was carried out by preparing an 
 α - ω -aminohexylcarbamate derivative of B 12 , which was then 
conjugated to carboxylated PS nanoparticles by standard car-
bodiimide chemistries. Cell studies were conducted using the 
Caco-2 (human intestinal) cell line cultured on permeable 
membrane supports, as a model of the intestinal epithelium 
that is most extensively used to study vitamin B 12 -mediated 
drug delivery. [ 8 , 22 , 23 ] These cell cultures exhibit unidirectional 
transport of vitamin B 12 in the apical-to-basolateral direc-
tion, [ 8 ] and also in an IF-dependent and IF-independent 
fashion. The latter is attributed to the expression of the 
receptor transcobalamin II-R (responsible for the internali-
zation of transcobalamin II in vivo) on the apical surface. [ 24 ] 
Initially the suitability of the Caco-2 cell culture model was 
verifi ed by confi rming the expression of cubilin receptor, as 
well as the presence and function of caveolae- and clathrin-
mediated endocytic pathways. 
 We discovered that the vitamin B 12 ligand-mediated 
pathway was affected and perturbed by the attachment of 
vitamin B 12 to the nanoparticles. Vitamin B 12 -nanoparticles 
bypassed the lysosomal compartments, with their cellular 
internalization and transport remaining largely unaffected 
by the inhibitors of clathrin-mediated endocytosis–the route 
governing vitamin B 12 -IF internalization in vivo. Cell inter-
nalization and transport behavior of B 12 -nanoparticles was 
instead markedly impeded by specifi c inhibitors of cav-
eolae-mediated endocytosis, demonstrating that vitamin 
B 12 -conjugated nanoparticles were traffi cked by a different 
intracellular pathway to both free vitamin B 12 and unmodi-
fi ed nanoparticles. Overall, our study demonstrates that the 
attachment of ligands to nanoscale carriers can perturb the 
natural biological pathway of the ligand: a phenomenon that 
can be potentially exploited for delivery of biotherapeutics. 
 2. Results 
 2.1. Characterization and Conjugation of 
 α - ω -Aminohexylcarbamate Vitamin B 12 to Functionalized 
Nanoparticles 
 The characterization and conjugation of amino-derivatized 
vitamin B 12 is shown in  Figure  1 . The 5′-hydroxyl group in the 
cyanocobalamin ribose ring was activated with 1,1′-carbonyl-
diimidazole (CDI) to be immediately derivatized with a slight 
excess of 1,6-hexanediamine (Figure  1 A). Derivatization of 
cyanocobalamin was confi rmed by means of nuclear magnetic 
resonance (NMR), mass spectrometry (MS), and high-perfor-
mance liquid chromatography (HPLC) (Supporting Informa-
tion, Figures S1-S5). Inspection of the  1 H-NMR signals for 
the ribose ring revealed that these signals were signifi cantly 
shifted after functionalization, especially those closer to the 
5′ hydroxyl group. In addition, new signals arising from the 
C6 linker could be observed (Figure  1 B and Supporting Infor-
mation, Figure S1). The purity of the material was confi rmed 
both by HPLC and MS, with the observed Mw of 1499.39 
(Supporting Information, Figures S4 and S5, respectively). 
 The synthesized  α - ω -aminohexylcarbamate vitamin B 12 
derivative was reacted with carboxy functionalized, fl uores-
cent (Yellow-Orange) PS nanoparticles in the presence of 
1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDAC) 
and  N -hydroxy-succinimide (NHS) to yield, after purifi cation 
by dialysis, the desired vitamin B 12 -conjugated nanoparticles 
(Figure  1 C). 
 The fl uorescence quenching property of vitamin B 12 
[ 25 , 26 ] 
was used in order to confi rm that conjugation of vitamin 
B 12 to nanoparticles had occurred (Supporting Information, 
Figure S6). The comparison of fl uorescence intensities showed 
a markedly lower fl uorescence for YO nanoparticles with 
surface conjugated vitamin B 12 , relative to that of unmodifi ed 
counterparts (Figure  1 D and Supporting Information, Figure 
S6A). Presence of free vitamin B 12 in a suspension of unmod-
ifi ed YO nanoparticles also resulted in a decrease in nano-
particle fl uorescence intensity with increasing amount of free 
vitamin B 12 (Supporting Information, Figure S6B), but the 
fl uorescence was in this case restored after removal of free 
vitamin B 12 by dialysis (Supporting Information, Figure S6C). 
On the contrary, for vitamin B 12 -conjugated nanoparticles, 
the fl uorescence intensity was not reversed following dialysis 
(Supporting Information, Figure S6C), confi rming that conju-
gation occurred. 
small 2013, 9, No. 19, 3282–3294
R. Fowler et al.
3284 www.small-journal.com © 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
full papers
 The vitamin B 12 quenching phenomenon was also 
exploited in an attempt to obtain quantitative information on 
the conjugation, by plotting the maximal emission peaks as 
a function of the weight percentage of free B 12 added (Sup-
porting Information, Figure S6B) to an exponential decay 
model (Supporting Information, Figure S6D) (R 2  ≥ 0.997). 
However, this resulted in an overestimation of B 12 attach-
ment to nanoparticles, as the obtained values exceeded those 
theoretically possible for shoulder-to-shoulder conjugation. 
This may be due to differences in the fl uorescence quenching 
effect of free and covalently bound vitamin B 12 . In fact, a 
red shift in fl uorescence was observed for the YO nanopar-
ticles in the presence of free B 12 , that was not detected in 
PS nanoparticles with covalently-bound B 12 (Figure  1 D and 
Supporting Information, Figure S6), which would be due the 
dependence of a quenching effect on diffusion and the dis-
tance between the two species. [ 27 ] 
 The extent of B 12 conjugation to nanoparticle surface 
depends on the number of functional acid groups available. 
To investigate this, potentiometric titration experiments 
on unmodifi ed nanoparticles (Supporting Information, 
Figure S7) estimated values for the number of carboxy 
groups per 1 nm 2 particle surface area to be 2.2 for 50 nm, 
8.9 for 100 nm, and 20.8 for 200 nm nanoparticles. Although 
it was not possible to confi rm this data with the nanoparticle 
manufacturer, the high surface density of acidic functional 
groups, also reported by others, [ 28 ] exceeds the number of 
ligand groups  per nm 2 required for theoretical shoulder-to-
shoulder conjugation of B 12 , assuming a 4 nm 
2 projected sur-
face area for vitamin B 12 . Therefore, it was reasoned that the 
level of B 12 conjugation to the nanoparticle surface would 
not be limited by the availability of acidic groups, but by the 
conjugation effi ciency. 
 The conjugation reaction employed an excess (10 mg) of 
vitamin B 12 derivative for all nanoparticle sizes (‘shoulder-
to-shoulder’ conjugation would require 1.85 mg, 0.92 mg, and 
0.46 mg B 12 for 50, 100, and 200 nm nanoparticles, respec-
tively). Considering that the conjugation effi ciency is not 
expected to be signifi cantly affected by nanoparticle size, 
and with an excess of both charged groups and vitamin B 12 
derivative (compared to amount required for shoulder-to-
shoulder conjugation), we would anticipate similar conjuga-
tion per surface area on the nanoparticles of all sizes, which 
would result in a similar spatial distribution of vitamin B 12 
ligand on the surface of 50 nm, 100 nm, and 200 nm nano-
particles. Nanoparticle-bound ligand presentation to the cells 
would therefore be similar, assuming its statistical distribu-
tion on the nanoparticle surface, which is important consid-
ering that the ligand surface density plays a role in cellular 
interaction and uptake of nanoparticulates. [ 29–33 ] 
 Particle size analysis demonstrated an increased average 
hydrodynamic radii and broader size distribution profi les 
for conjugated, relative to unmodifi ed, nanoparticles (Sup-
porting Information, Figure S8). However, the observed 
average particle size falls within the size limits that could 
potentially affect the cell internalization behavior of nano-
particles. [ 21 ] It should be noted that all nanoparticles in this 
work are referred according to the size specifi ed by the man-
ufacturer; in the case of B 12 -conjugated nanoparticles, this 
size is the pre-conjugation size. Vitamin B 12 conjugation was 
 Figure  1 .  A) Synthesis of  α - ω -aminohexylcarbamate-vitamin B 12 (schematic). B)  
1 H-NMR (expanded region) of purifi ed vitamin B 12 (labelled 
‘B12’) and  α - ω -aminohexylcarbamate-vitamin B 12 (labelled ‘B12-NH 2 ’). C) Schematics of the  α - ω -aminohexylcarbamate-vitamin B 12 conjugation 
to fl uorescent Yellow-Orange carboxylated polystyrene nanoparticles (‘YO-NP’). D) Fluorescent spectra of YO (50 nm) unmodifi ed nanoparticles 
(‘Unmodifi ed’), unmodifi ed YO nanoparticles in the presence of vitamin B 12 in solution (‘Unmodifi ed  + 22% w/w VB 12 ’) and vitamin B 12 -conjugated 
YO (50 nm) nanoparticles (‘VB 12 conjugated’). Detailed characterization of both  α - ω -aminohexylcarbamate-vitamin B 12 and B 12 -conjugated 
nanoparticles is included in Supporting Information. 
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also indicated by a decrease in zeta poten-
tial values of the conjugated, relative to 
unconjugated nanoparticles (Supporting 
Information, Table S1). However, the 
decreased zeta potential values (measured 
in the biological solution in which the nan-
oparticles were applied to the cells) were 
suffi cient to provide charge stabilization of 
the nanoparticle colloidal suspension. 
 2.2. Cell Uptake and Transport of Vitamin 
B 12 -Conjugated Nanoparticles 
 Cell uptake studies ( Figure  2 A) demon-
strate that internalization of 50 nm vitamin 
B 12 -conjugated nanoparticles occurred to 
a markedly greater extent, amounting to 
28  µ g/cm 2 (nanoparticle amount per cell 
monolayer area) following a 3-h experi-
ment, as compared to unmodifi ed nanoparticles of the same 
size, which corresponded to 1.5  µ g/cm 2 . Furthermore, a com-
petitive inhibition study reveals that the cellular uptake of 
vitamin B 12 -conjugated nanoparticles was notably inhib-
ited by the presence of excess soluble vitamin B 12 , from 
28  µ g/cm 2 to 1.7  µ g/cm 2 (Figure  2 A), indicating vitamin 
B 12 receptor involvement in the process of cell uptake of 
vitamin B 12 -conjugated nanoparticles. Regarding transcel-
lular transport of nanoparticles, the experiments (Figure  2 B) 
demonstrate a signifi cantly increased translocation of 
B 12 -conjugated nanoparticles across the cell monolayers, 
relative to the unmodifi ed counterparts, with a level of trans-
port of 7.3  µ g/cm 2 and 1.3  µ g/cm 2 (in a 2-hour experiment), 
respectively. The transcellular transport was reduced in the 
competitive experiment where B 12 -conjugated nanoparticles 
were co-applied with excess free vitamin B 12 to 1.4  µ g/cm 2 . 
 2.3. Effect of Nanoparticle Size on Cell Uptake and Transport 
of Vitamin B 12 -Conjugated Nanoparticles 
 In terms of the mass of nanoparticles, vitamin B 12 -conjugation 
promoted a signifi cant increase in cell internalization for 50 
and 100 nm-sized nanoparticles, as compared to unmodi-
fi ed nanoparticles ( Figure  3 A), with the level of inter-
nalization of 39  µ g/cm 2 for 100 nm and 32  µ g/cm 2 for 
50 nm nanoparticles. Cell uptake of B 12 -conjugated nano-
particles of 200 nm (8  µ g/cm 2 ) was, however, not statisti-
cally different to unmodifi ed nanoparticles of the same size 
(6  µ g/cm 2 ) (Figure  3 A). Expressing the same data in terms 
of the number of nanoparticles, it is apparent that 50 nm 
B 12 -conjugated nanoparticles were taken up by the cells in 
the greatest number (4.7  × 10 11 /cm 2 ), followed by 100 nm 
(7.1  × 10 10 ) and 200 nm nanoparticles (1.7  × 10 9 ). 
 Data showing transport of vitamin B 12 -con-
jugated nanoparticles across the cell monolayers 
(Figure  3 B) reveals that an increase in nanoparticle size from 
50 to 100 nm resulted in an increased mass of translocated 
nanoparticles, from 5.8  µ g to 14  µ g. This is reduced to 1.4  µ g 
 Figure  3 .  Effect of particle size on cell uptake and transport of vitamin 
B 12 -conjugated nanoparticles in Caco-2 monolayers. A) Cell uptake 
expressed as mass (bar, left y-axis) and number (line, right y-axis) of 
nanoparticles per surface area of the cell monolayer. B) Transport across 
the cell monolayers expressed as mass (bar, left y-axis) and number of 
nanoparticles (line, right y-axis) per surface area of the cell monolayer. 
Data represents the mean  ± SD (n  = 3). Statistical analysis compared 
mass values for cell uptake and transport. Statistical comparisons 
indicated in the graphs: 100 nm vs 50 nm and 200 nm vs 100 nm 
for B 12 -conjugated nanoparticles and B 12 -conjugated vs unmodifi ed 
nanoparticles of the same nominal size. 
 Figure  2 .  Cell uptake and transport of unmodifi ed and vitamin B 12 -conjugated nanoparticles 
in Caco-2 monolayers. A) Cell uptake of B 12 -conjugated nanoparticles, alone or in the presence 
of excess ‘free’ vitamin B 12 (500  µ g) in medium, and uptake of unmodifi ed nanoparticles. 
B) Transport of B 12 -conjugated nanoparticles across the cell monolayers, alone or in the 
presence of excess ‘free’ B 12 , and transport of unmodifi ed nanoparticles. Yellow-Orange PS 
nanoparticles of 50 nm nominal diameter were used. All experiments were conducted in the 
presence of intrinsic factor (IF). Data represents the mean  ± SD (n  = 3). 
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with a further increase in nanoparticle 
size to 200 nm. Considering the number 
of nanoparticles transported across the 
cell monolayers, there was a decrease from 
8.5  × 10 10 to 2.6  × 10 10 to 3.2  × 10 8 as nano-
particle size increased from 50 nm to 100 nm 
and 200 nm, respectively, indicating a 3-fold 
reduction in transport when nanoparticle 
diameter increased from 50 to 100 nm, 
and a substantial 81-fold reduction in 
transport for the size increase from 100 to 
200 nm. 
 2.4. Intracellular Localization of Vitamin 
B 12 -Conjugated Nanoparticles 
 Two complementary techniques were 
employed, as shown in  Figure  4 , to assess 
whether B 12 -conjugated nanoparticles 
reached the lysosomal compartment–the 
terminal destination of the IF-B 12 com-
plex following its cell internalization. 
The Lysotracker probe was used to iden-
tify active lysosomal compartments, [ 34 ] 
whereas immunostaining for lysosomal 
associated membrane protein (LAMP1) 
was employed as a marker for a structural 
component of the lysosomes. [ 35 , 36 ] Since 
LAMP1 protein is ubiquitously expressed 
in the cells, anti-LAMP1 antibody was 
used in this case to identify localized or 
clustered protein regions, likely to be 
representative of lysosomal structures. 
Control confocal imaging experiments 
conducted on cell monolayers that were 
not exposed to nanoparticles illustrate 
the absence of Lysotracker green staining 
(Figure  4 A), attributable to the existence 
of small, inactive primary lysosomes, [ 37 ] 
as well as the potential loss of staining 
during cell fi xation. [ 38 ] Similarly, these con-
trol experiments also show a low level of 
LAMP1 immunostaining (Figure  4 B). 
 Application of unmodifi ed nanopar-
ticles to Caco-2 monolayers resulted in 
their co-localization with the Lysotracker 
marker (Figure  4 C). A series of control 
experiments ensured that the imaged pat-
tern did not result from potential cross-
emission between the YO fl uorophore 
of nanoparticles and Lysotracker (Sup-
porting Information, Figure S9). Impor-
tantly, cells incubated with unlabelled, 
unmodifi ed nanoparticles (stained and 
imaged under the Lysotracker settings) 
displayed a similar punctate Lysotracker 
staining pattern (Supporting Information, 
Figure S9E) to cells imaged following 
 Figure  4 .  Confocal micrographs showing the uptake of B 12 -conjugated nanoparticles (50 nm 
diameter) by Caco-2 monolayers. A) Cell staining with Lysotracker Green DND-26 in the absence 
of nanoparticles. B) Immunostaining for lysosomal associated-membrane protein 1 (LAMP1, 
green) in the absence of nanoparticles. C) Co-localisation of unmodifi ed nanoparticles (red) 
with Lysotracker Green DND-26 (green), appearing as orange in some areas of the image. 
D) Immunostaining for LAMP1 protein (green) following cell incubation with unmodifi ed 
nanoparticles (red). E) Staining with Lysotracker Green DND-26 (green) after cell incubation with 
vitamin B 12 -conjugated nanoparticles (red). F) Immunostaining for LAMP1 (green) following 
exposure of cells to vitamin B 12 -conjugated nanoparticles (red). Lysotracker Green DND-26 
excitation 504 nm, emission 511 nm; YO nanoparticle excitation 529 nm, emission 546 nm; 
cell nuclei stained with Hoechst 33342 (blue). Scale bars indicated within individual images. 
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application of unmodifi ed YO (fl uorescent) nanoparticles, 
indicating that this lysosomal probe is detectable in the pres-
ence of nanoparticles when larger lysosomal bodies are pre-
sent (retaining the dye during cell fi xation stage). Figure  4 C, 
in conjunction with the control experiments in Figure S9, 
hence confi rms the co-localisation of lysosomal Lysotracker 
stain and unmodifi ed nanoparticles and that this is not an 
experimental artefact. On the contrary, following the appli-
cation of vitamin B 12 -conjugated nanoparticles to the cells, 
staining of lysosomal compartments with Lysotracker probe 
could not be observed (Figure  4 E). 
 It should be noted that the potential 
buffering of lysosomes by internalized 
B 12 -conjugated nanoparticles, and conse-
quent absence of Lysotracker accumula-
tion in acidic compartments, can be ruled 
out as the Lysotracker accumulation is 
clearly seen in Figure  4 C when unmodifi ed 
nanoparticles were applied and the pres-
ence of vitamin B 12 molecules does not 
afford buffering capability to the conju-
gated nanoparticles. 
 Regarding LAMP1 immunostaining, 
which is a marker for a lysosomal mem-
brane protein, an indication of active 
lysosomes would be the formation of rela-
tively larger structures, seen as globular 
regions following application of unmodifi ed 
nanoparticles (Figure  4 D), as opposed to a 
diffused fl uorescence distribution pattern 
throughout the cytosol on application of 
B 12 -conjugated nanoparticles (Figure  4 F). 
 2.5. Cubilin Receptor, Caveolin-1, and 
Clathrin Expression in Caco-2 Cells 
 To validate the appropriateness of Caco-2 
monolayers as a model to study the epi-
thelial traffi cking of vitamin B 12 , the 
expression of the appropriate cellular 
components implicated in the vitamin B 12 
pathway, including the vitamin B 12 cell 
surface receptor (cubilin), components 
of clathrin-coated pits (implicated in the 
internalization of the soluble B 12 -IF com-
plex) and caveolae (another possible route 
for material internalization), was con-
fi rmed ( Figure  5 ). Confocal micrographs 
(Figure  5 Ai) reveal positive fl uores-
cence signal from cubilin receptor immu-
nostaining, strongly suggesting expression 
of this protein in Caco-2 cells. The lack of 
fl uorescence in the control experiment, 
where cell incubation with the primary 
antibody was omitted, rules out experi-
mental artefacts that may result from non-
specifi c antibody binding (Figure  5 Aii). 
Cell monolayers also stained positively 
for the expression of clathrin, as a protein responsible for the 
formation of clathrin ‘coated-pits’ (Figure  5 Bi and control 
experiment in 5Bii). 
 There are contradictory reports regarding the presence of 
caveolin-1 in Caco-2 cells and their ability to internalize mate-
rial via caveolae-like domains. [ 39–42 ] Expression of caveolin-1 
protein in cells is generally considered suffi cient and neces-
sary to drive the formation of morphologically identifi able 
caveolae. [ 43–45 ] Staining for caveolin-1 protein (Figure  5 Ci 
and ii) clearly indicates its presence in the Caco-2 
monolayers. It should be noted that cells were permeabilized 
 Figure  5 .  Immunostaining for cubilin receptor and selected endocytic components in Caco-2 
cells, cultured as monolayers. A) i) Expression of cubilin receptor in cells treated with anti-
human cubilin H300, followed by goat, anti-rabbit IgG-Rhodamine antibody (red) and 
ii) Control monolayer treated with the secondary, goat, anti-rabbit IgG-Rhodamine antibody 
only. B) i) Expression of clathrin, demonstrated by cell treatment with rabbit anti-clathrin 
primary antibody and goat, anti-rabbit IgG-FITC (green), and ii) Control monolayer treated with 
the secondary, goat, anti-rabbit IgG-FITC antibody only. C) i) Expression of caveolin-1, shown 
by treating cells with anti-human caveolin-1 H-97 antibody, followed by secondary goat, anti-
rabbit IgG-Rhodamine antibody (red), and ii) Control monolayer, incubated with goat anti-
rabbit IgG-Rhodamine antibody only. Cell nuclei were labelled with Hoechst 33342 (blue) in 
all cases. Immunostaining for all components was performed on day 21 of transwell culture. 
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prior to staining, in accordance with the generally accepted 
view that both the NH 2 - and the COOH- termini of cave-
olin-1 face the cytoplasm and that no portion of the protein is 
extracellular. [ 46 , 47 ] 
 2.6. Cell Traffi cking of Soluble Vitamin B 12 
 The previously documented cell uptake 
and transport mechanism of vitamin B 12 -IF 
was confi rmed initially by applying specifi c 
inhibitors of clathrin- and caveolae-medi-
ated endocytosis. The uptake and trans-
port-inhibiting effects of chlorpromazine 
(clathrin inhibition) and fi lipin (caveolae 
inhibition) in Caco-2 monolayers were ini-
tially validated by applying the pathway-
selective ligands, transferrin [ 48 , 49 ] and 
cholera toxin B-subunit, [ 42 , 50 ] respectively 
(Supporting Information, Figure S10A–
D). The internalization ( Figure  6 A) and 
transport (Figure  6 B) of soluble vitamin 
B 12 were sensitive to the effects of chlor-
promazine-mediated inhibition of the 
clathrin pathway (4-fold decrease) and 
were not signifi cantly affected by the 
action of caveolae inhibitor, fi lipin. The 
data hence demonstrates that soluble 
vitamin B 12 (co-applied with IF) exploited 
a clathrin-mediated route in Caco-2 cells. 
 2.7. Cell Traffi cking of Vitamin B 12 -Conju-
gated Nanoparticles 
 Studies to decipher the cell traffi cking 
pathways of vitamin B 12 -conjugated nano-
particles initially employed chlorproma-
zine and fi lipin as pathway inhibitors, 
followed by additional experiments where 
clathrin- or caveolae-mediated pathways 
were inhibited by the way of potassium 
depletion [ 21 , 51 ] or genistein treatment, [ 52 , 53 ] 
respectively ( Figures  7 and  8 ). 
 Chlorpromazine treatment did not 
produce a statistically signifi cant reduction 
in the extent of cellular uptake of vitamin 
B 12 -conjugated nanoparticles (Figure  7 Ai). 
This is in contrast to the experiment 
shown in Figure  6 A, which depicts a sig-
nifi cant chlorpromazine-induced inhi-
bition of cell internalization of soluble 
vitamin B 12 under comparable conditions. 
Considering the effect of chlorproma-
zine on the transport of vitamin B 12 -con-
jugated nanoparticles across the cells, 
Figure  7 Aii shows a steady state transport 
in chlorpromazine-treated cells compared 
to a rapid initial rate, followed by a later 
decrease in rate, in untreated cells. Consequently, the amount 
of vitamin B 12 -conjugated nanoparticles transported across 
the cells at the 3-hour measurement point reached the value 
seen in untreated cells. It is not entirely clear why such an 
 Figure  6 .  Effect of endocytic pathway-specifi c inhibitors on cell uptake and transport of 
soluble, ‘free’ vitamin B 12 . A) Effect of chlorpromazine and fi lipin on cell uptake of vitamin B 12 . 
B) Effect of chlorpromazine and fi lipin on transport of vitamin B 12 across Caco-2 monolayers. 
‘Untreated ‘free’ B12’ denotes experiment in absence of inhibitors, ‘Filipin (5  µ g/mL) treated’ 
denotes cell treatment with fi lipin, and ‘Chlorpromazine (10  µ g/mL) treated’ denotes cell 
treatment with chlorpromazine. Vitamin B 12 was applied in presence of IF. Data represents 
the mean  ± SD (n  = 3). 
 Figure  7 .  Effect of clathrin inhibition on cell uptake and transport of vitamin B 12 -conjugated 
nanoparticles. A) Effect of chlorpromazine on (i) cell uptake and (ii) transport. B) Effect of 
potassium depletion on (i) cell uptake and (ii) transport. Studies were conducted with B 12 -
conjugated nanoparticles of 50 nm nominal diameter and in the presence of IF. ‘Untreated B12-
conjugated nanoparticles’ denotes experiment in the absence of inhibitors, ‘Chlorpromazine 
(10  µ g/ml) treated’ denotes cell treatment with chlorpromazine, ‘B12-conjugated 
nanoparticles (potassium depleted)’ denotes potassium depletion of cell medium and ‘B12-
conjugated nanoparticles (potassium supplemented)’ denotes potassium supplementation 
of the medium. Data represents the mean  ± SD (n  = 3). 
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effect on transport was apparent, though it may have resulted 
from chlorpromazine interference with cytoskeletal function 
and consequent decreased transport of material towards the 
basolateral membrane. [ 54 , 55 ] It is important, however, that 
the curve profi le in the Figure  7 Aii is dramatically different 
the chlorpromazine inhibition seen in Figure  6 B, indicating 
a clear difference of chlorpromazine effects on the transport 
of soluble vitamin B 12 and B 12 -conjugated nanoparticles. In 
addition, the curve in Figure  7 Aii is distinctly different to the 
profi le in Figure S10B (Supporting Information) where trans-
port of the pathway-selective ligand for clathrin (transferrin) 
is inhibited by the chlorpromazine-induced effect on clathrin-
mediated pathway. 
 The data from experiments conducted in potassium-
depleted medium again indicate no signifi cant effect on cell 
uptake of vitamin B 12 -conjugated nanoparticles when the 
clathrin pathway is inhibited, relative to the appropriate con-
trol (potassium supplemented medium) (Figure  7 Bi). Like-
wise, potassium depletion did not affect the transport of 
B 12 -conjugated nanoparticles relative to the unmodifi ed con-
trol (Figure  7 Bii). However, it must be noted that nanoparticle 
transport across the cell monolayers is markedly lower in the 
medium used in the potassium depletion experiments, even in 
the control experiment, compared to routinely used HBSS. 
 Treatment of cells by fi lipin (cave-
olae inhibitor) gave rise to a pronounced 
reduction in cell internalization of vitamin 
B 12 -conjugated nanoparticles by approxi-
mately 5-fold (Figure  8 Ai). The effect is 
mirrored in the signifi cant inhibition of 
transport across the cell monolayers of 
vitamin B 12 -nanoparticles in the pres-
ence of the same inhibitor (Figure  8 Aii), 
whereby a level of transport of 5.8  µ g in 
untreated cells was reduced to 1.2  µ g in 
fi lipin-treated cell monolayers. Applica-
tion of an alternative inhibitor specifi c for 
the caveolae endocytic pathway, genistein, 
again demonstrated a similar 5-fold reduc-
tion in cell uptake of vitamin B 12 -conju-
gated nanoparticles (Figure  8 Bi) and a 
dramatic suppression in their transport 
(Figure  8 Bii). 
 Control experiments determining the 
uptake pathway of unmodifi ed nanoparti-
cles revealed that the inhibition of either 
clathrin or caveolae traffi cking pathways 
did not produce a signifi cant effect on 
the uptake and transport of non-function-
alized 50 nm sized nanoparticles (Sup-
porting Information, Figure S11). 
 3. Discussion 
 With recent developments in nano scale-
based therapeutics there is a need to 
understand the processes of nanoparticu-
late interaction with the biological sys-
tems, including their traffi cking by cells. An understanding 
of the biological pathways by which ligand-functionalized 
nanoparticle carriers engage whilst delivering their thera-
peutic payload is crucial for the development of such sys-
tems for a variety of clinical applications. The vitamin B 12 
biological pathway has previously been considered for oral 
delivery of protein therapeutics and nanoparticle drug car-
riers. With respect to the latter, the cell traffi cking mecha-
nisms by which B 12 -bearing nanosystems traverse the 
intestinal epithelium remain unstudied. 
 Here we investigated the traffi cking of vitamin 
B 12 -conjugated model (polystyrene) nanoparticle carrier 
in an intestinal epithelial cell model. To enable this, car-
boxy-functionalized, fl uorescent nanoparticles were sur-
face modifi ed with the  α - ω -aminohexylcarbamate vitamin 
B 12 derivative. Vitamin B 12 was amino derivatized using a 
5′-ribose carbamate linkage, as such carbamate derivatives 
provide an increased affi nity towards IF, [ 56 ] and the linkage 
is stable under the acidic conditions of the stomach. [ 56 ] Deri-
vatization of cyanocobalamin was confi rmed by NMR, MS 
and HPLC (Supporting Information, Figures S1–S5), whilst 
the fl uorescence quenching property of vitamin B 12 
[ 25 , 26 ] was 
used to confi rm B 12 conjugation (Supporting Information, 
Figure S6) following removal of ‘free’ vitamin B 12 by dialysis. 
 Figure  8 .  Effect of caveolae inhibition on the uptake and transport of vitamin B 12 -conjugated 
nanoparticles. A) Effect of fi lipin on (i) cell uptake and (ii) transport of nanoparticles. B) Effect 
of genistein on (i) cell uptake and (ii) transport of nanoparticles. 50 nm vitamin B 12 -conjugated 
nanoparticles applied in the presence of IF. ‘Filipin (5  µ g/mL) treated’ denotes cell treatment 
with fi lipin, ‘Untreated B12-conjugated nanoparticles’ denotes experiment in absence of 
inhibitor and ‘Genistein (200  µ M) treated’ denotes cell treatment with genistein. It should be 
noted that the control experiment depicting transport of B 12 -conjugated nanoparticles across 
untreated cells, presented in Figure 7Aii, is also a control for this inhibition experiment. Data 
represents the mean  ± SD (n  = 3). 
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 Vitamin B 12 -conjugated nanoparticles exhibited a 
notably different behaviour, compared to unmodifi ed nano-
particles, in terms of their cellular internalization and trans-
port across the epithelial Caco-2 cell monolayers. Surface 
conjugation of B 12 signifi cantly enhanced the uptake by 
and transport of nanoparticles across the polarized cells 
(Figures  2 and  3 ), whilst inhibition of these processes in the 
presence of excess soluble (‘free’) vitamin B 12 (Figure  2 ) 
suggests that the traffi cking of B 12 -conjugated nanoparticles 
in Caco-2 cells occurs through a vitamin B 12 -mediated bio-
logical pathway. 
 Numerous published studies assessed the impact of par-
ticle size on their cellular uptake in vitro, [ 57 , 58 ] however rather 
fewer studies [ 8 , 59 ] have been conducted with systems where 
ligand-modifi ed nanoparticles of specifi c size ranges were 
utilized to target epithelial transport pathways. This study 
employed vitamin B 12 -conjugated 50, 100, and 200 nm PS 
lattices, encompassing the generally accepted size range for 
endocytosis in epithelial cells, to assess the biological mecha-
nisms involved in the process of nanoparticle translocation 
across the Caco-2 epithelial barrier. Data was expressed in 
terms of nanoparticle mass (important from the drug delivery 
perspective), as well as nanoparticle number (potentially sig-
nifi cant in understanding the number of events occurring). 
The data clearly demonstrates that, concerning the number 
of events occurring, an increase in nanoparticle size results in 
a decrease in the number of nanoparticles internalized, with 
this decrease being notably more prominent between 100 and 
200 nm nanoparticles (41-fold), compared to that between 50 
and 100 nm nanoparticles (approximately 7-fold). However, 
for mucosal delivery of therapeutics aiming to achieve a 
systemic effect, it would be desirable to obtain an absorption 
level that is suffi ciently high to achieve a therapeutic effect. 
To this end, the amount of 14  µ g/cm 2 , which was found to 
traverse the cell monolayers in the case of 100 nm nanopar-
ticles is signifi cantly higher than that of 50 nm nanoparticles 
(5.8  µ g/cm 2 ) and 200 nm systems (1.4  µ g/cm 2 ). Addition-
ally, vitamin B 12 -conjugated nanoparticles of 50 and 200 nm 
were found to translocate across the cell monolayers less 
effi ciently, with approximately 1 in 5.5 of internalized nano-
particles transported in both cases, relative to 100 nm nano-
particles where 1 in 2.8 of internalized nanoparticles crossed 
the cell monolayer barrier (Figure  4 ). One would therefore 
conclude that 100 nm nanoparticle systems could achieve 
optimal delivery capacities for a vitamin B 12 -mediated oral 
delivery. 
 In the process of cell traffi cking of soluble vitamin B 12 
in vivo , the IF-B 12 complex is believed to be transported to 
the lysosome, where IF protein is degraded to release B 12 . 
[ 16 ] 
From the perspective of transmucosal delivery of biologic 
drugs, this would mean that the B 12 -modifi ed nano-carrier 
(together with its active therapeutic) reaches the highly 
degradative lysosomal compartment, hence undermining its 
delivery potential. However, whether the intracellular traf-
fi cking of vitamin B 12 -conjugated nano-carrier follows that 
same path has not been previously described in the litera-
ture. We hence employed B 12 -conjugated 50 nm nanoparti-
cles (particles of this size can enter the cells by different cell 
internalization pathways) and conducted a series of confocal 
(co-localization) and transport inhibition studies to deci-
pher their intracellular traffi cking. The data depicts that, 
unlike unmodifi ed PS nanoparticles, vitamin B 12 -conjugated 
counterparts did not co-localize with a marker for lysosomes 
(Figure  4 ), indicating that surface decoration of nanoparticles 
with vitamin B 12 gives rise to lysosomal bypass, hence sug-
gesting a switch in cellular traffi cking relative to both unmod-
ifi ed nanoparticles, as well as the route proposed for soluble 
vitamin B 12 . The apparent weaker fl uorescence intensity of 
vitamin B 12 -conjugated nanoparticles compared to unmodi-
fi ed counterparts is a consequence of fl uorescence quenching 
effect of vitamin B 12 . 
 The cell traffi cking pathway of soluble vitamin B 12 in vivo 
is relatively well established; B 12 initially binds to IF, followed 
by binding of B 12 -IF complex to the cubilin receptor situated 
in the apical brush border membrane of the ileal mucosa. [ 60 ] 
Association of cubilin receptor with megalin, a member of 
the LDL receptor-related family of endocytic receptors, [ 61 , 62 ] 
leads to internalization of the entire cubilin receptor-IF-B 12 
complex via clathrin-coated vesicles. [ 17 ] Our study initially 
confi rmed the role of clathrin in the process of cell inter-
nalization of soluble vitamin B 12 (applied in combination 
with IF) in Caco-2 cells, as suggested by chlorpromazine-
induced inhibition, while cellular transport remained largely 
unaffected by caveolae inhibitor, fi lipin (Figure  6 ). [ 21 , 42 , 50 ] In 
this experiment, both soluble vitamin B 12 and IF were used 
at a higher than physiological doses, [ 63 ] as the study was 
not designed to assess the absorption capacity of B 12 but to 
unravel the pathways involved in the process of epithelial 
transit. Similar levels of soluble vitamin B 12 transport across 
the Caco-2 monolayers obtained in this study (apparent per-
meability coeffi cient equivalent to 7.54  × 10  − 7 cm/s) have also 
been reported in earlier studies employing comparatively 
high doses of vitamin B 12 in Caco-2 cells, 
[ 64 , 65 ] and may partly 
be contributed by passive paracellular transport, as suggested 
for other vitamin B family sub-types following high dose 
application. [ 66 ] 
 Experiments to elucidate the cell traffi cking mechanism(s) 
of vitamin B 12 -conjugated nanoparticles indicated that 
clathrin inhibition by chlorpromazine did not signifi cantly 
affect the extent of their cell internalisation (as measured 
at 3 hours time point). However, considering the transport 
of B 12 -conjugated nanoparticles across the cell layers in the 
presence of chlorpromazine, an inhibitory effect is present in 
the initial phase, relative to the control experiment, however 
the overall amount transported over the 3-hour experiment 
was not signifi cantly affected (Figure  7 A). The transport pro-
fi le is dramatically different to a pathway selective ligand 
(Supporting Information, Figure S10B). Furthermore, cell 
uptake and transport of B 12 -bearing nanoparticles was not 
affected in the potassium-depleted medium (Figure  7 B), used 
as an alternative approach for clathrin pathway inhibition. 
This strengthens the suggestion, as derived from our data, 
that the clathrin pathway does not play a major role in traf-
fi cking of vitamin B 12 -conjugated nanoparticles, although 
some involvement cannot be excluded. On the other hand, 
treatment with either fi lipin or genistein, as caveolae-inhib-
iting agents, resulted in a pronounced reduction in cellular 
internalization and transport of vitamin B 12 -bearing nano-
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particles (Figure  8 A and B). Interestingly, inhibition of either 
clathrin or caveolae traffi cking pathways did not demonstrate 
a signifi cant effect on the uptake and transport of unmodi-
fi ed nanoparticles, implying alternative (i.e. non-clathrin and 
non-caveolae) routes in their cell uptake and transport (Sup-
porting Information, Figure S11). This further confi rms that 
the involvement of the caveolar route is indeed specifi c to 
the B 12 -conjugated nanoparticles. 
 The fi nding that vitamin B 12 -bearing nanoparticles (in the 
presence of IF) predominantly exploit the caveolae-mediated 
route and evade lysosomes was not expected. The ‘switch’ in 
cell entry and intracellular traffi cking could potentially result 
from the nature of vitamin B 12 ligand presentation to the 
cells. Presentation of multiple, particle-immobilised ligands in 
close proximity offers the possibility of a different interaction 
with IF and the cubilin receptor at the cell membrane, which 
following association with megalin receptor may trigger the 
caveolae rather than the clathrin pathway. Megalin receptor 
driven endocytosis has typically been associated with clathrin 
coated pits, although recent publications indicate the possi-
bility of caveolae pathway involvement. [ 67 , 68 ] 
 4. Conclusion 
 We demonstrated that the surface-conjugation of vitamin B 12 
to nanoparticles results in an unexpected intracellular traf-
fi cking behaviour in polarized epithelial cells, with a ‘switch’ 
in pathway: a fi nding that may have important implications 
for oral delivery of ligand-based nanoscale therapeutics and 
diagnostics. Considering that in the process of vitamin B 12 
absorption in vivo, lysosomal function is essential for degrada-
tion of the associated IF, [ 17 ] further studies are necessary to 
ascertain whether vitamin B 12 -conjugated nanoparticles retain 
IF on exit from the cells and if so, what are the consequences 
from a therapeutic perspective. However, the synergistic par-
ticle size and ligand decoration effects observed in epithelial 
cultures on the intracellular traffi cking of B 12 -conjugated 
nanoparticles is, to the best of our knowledge, a previously 
unreported example of controlled pathway switching in this 
way. These fi ndings may provide signifi cant new insights and 
chemical ‘design rules’ for nanoparticulate systems, which 
could enable their practical use in delivery of therapeutic and 
diagnostic macromolecules across the intestinal epithelium. 
 5. Experimental Section 
 Solid 1,1’-carbonyldiimidazole (CDI), anhydrous dimethyl sulfoxide, 
cyanocobalamin and  N -hydroxy-succinimide (NHS) were purchased 
from Acros®. 1,6-hexanediamine, ethyl acetate and acetone were 
obtained from Fisher Scientifi c. 1-ethyl-3-[3-dimethylaminopropyl]
carbodiimide (EDAC) was purchased from Calbiochem and all other 
chemicals and materials, unless otherwise stated, were purchased 
from Sigma-Aldrich or Fisher Scientifi c. 
 Thin layer chromatography (TLC) was conducted on silica gel 
F 254 from Fluka (Sigma-Aldrich) ( 
 i  PrOH 30 mL/ n -BuOH 45 mL/H 2 O 
21 mL/NH 4 OH 4 mL/TEA 1 mL). Mass spectra were recorded on a 
Waters ZMD spectrometer with a capillary voltage of 3.5 kV, a source 
temperature of 120  ° C and a desolvation temperature of 350  ° C. 
 Preparative high performance liquid chromatography 
(HPLC) of the product was carried out using a Waters and Asso-
ciates system using a Waters X-Bridge C18 column (100  × 
19 mm). The vitamin B 12 product was eluted with 100% water con-
taining 10 mM ammonium formate and 0.1% (v/v) of ammonia 
solution (pH 9.5, solvent A) and 95% acetonitrile (Fisher Chemical, 
HPLC gradient grade) with 5% water and 0.1% ammonia solu-
tion (in water) (solvent B), using a gradient system at 20 mL/
min comprising linear gradients from 3% to 10% v/v solvent B at 
2 min, 35% v/v solvent B at 11.5 min and 95% v/v solvent B at 
12 min. Purity ( > 95%) was determined using a Waters analytical 
HPLC system with a Waters 996 photodiode array detector at wave-
lengths 230–400 nm. NMR spectra of the product and starting 
material (cyanocobalamin) were obtained using a Bruker AV600 
spectrometer equipped with a 5 mm TXI ( 1 H,  13 C,  15 N) cryoprobe 
running TopSpin v2.1 in deutero-methanol (CD 3 OD) solution. This 
method was adapted from McEwan et al. [ 56 ] 
 5.1. Preparation of the  α - ω -Aminohexylcarbamate Derivative 
of Cyanocobalamin 
 Solid CDI (260 mg, 0.32 mmol) was added to cyanocobalamin (1.0 g, 
0.148 mmol) previously dissolved in anhydrous dimethyl sulfoxide 
(12 mL). The mixture was stirred for 1–2 h at 30  ° C. Dry 1,6-hexan-
ediamine (314 mg, 0.54 mmol) was added and the mixture stirred 
at room temperature over 24 h. The mixture was poured into ethyl 
acetate (30 mL) and left to stand. Following brief centrifugation, the 
supernatant was decanted and the residue sonicated for 5 min in 
acetone (50 mL). The resulting precipitate was fi ltered and the solid 
washed in acetone. The crude product was purifi ed by silica column 
chromatography (45% v/v 2-propanol, 30% v/v n-butanol, 2% v/v 
ammonia and 25% v/v water) and then lyophilised. 
 5.2. Preparation of Vitamin B 12 -Conjugated Nanoparticles 
 Fluorescent carboxylate Yellow Orange (YO, fl uorescence spectra 
equivalent to rhodamine) polystyrene (PS) nanoparticles of 50 nm, 
100 nm, and 200 nm (PolySciences Inc, 1 mL of 2.69, 2.6 and 
2.63% w/v aqueous suspension, respectively) were modifi ed with 
the  α - ω -aminohexylcarbamate vitamin B 12 derivative (10 mg) by 
activation with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
(EDAC), in the presence of  N -hydroxy-succinimide (NHS). The reac-
tion was left to proceed for 5 h followed by incubation with glycine 
(100 mg/mL) in 50 mM carbonate buffer, pH 9.5, to block residual 
activated carboxyl sites. The particles were dialyzed extensively 
against distilled water over 24 h, with the water exchanged at reg-
ular intervals. 
 5.3. B 12 -Conjugated Nanoparticle Characterization 
 The fl uorescence quenching properties of vitamin B 12 
[ 25 , 26 ] were 
used to demonstrate the conjugation of the ligand on the sur-
face of fl uorescent carboxylated polystyrene (PS) nanoparticles 
following dialysis to remove free ligand (Supporting Information, 
Figure S6). Fluorescence spectra of both vitamin B 12 -conjugated 
and unmodifi ed nanoparticles (400  µ g/mL) were recorded on a 
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Cary Eclipse fl uorimeter ( λ ex  = 529 nm). The unmodifi ed nanopar-
ticle suspensions were titrated with increasing amounts of cyano-
cobalamin (in 2–8  µ g steps), which in order to prevent dilution of 
nanoparticles upon titration, was applied dissolved in the nano-
particle suspension. Spectra were recorded after each addition 
and calibration curves were generated based on percent weight 
of vitamin B 12 to nanoparticles against fl uorescence intensity and 
fi tted to an exponential decay model. 
 The concentration of carboxyl groups on the nanoparticles 
was determined from potentiometric titration. Experiments were 
conducted with unmodifi ed nanoparticles (50, 100, 200 nm), 
using a Fisher brand Hydrus 600 pH meter and a Thermo Fisher 
Orion 911 pH electrode at room temperature (23  ° C). Unmodi-
fi ed nanoparticles were diluted 1:5 using distilled water. The pH 
of the nanoparticle suspensions was lowered to 1.70 using 1 M 
HCl. Stepwise additions of 0.1 M NaOH were made until neutral pH 
was attained. The concentration of carboxyl groups was calculated 
from the difference between the number of moles of HCl originally 
added and those of NaOH used for neutralisation. The density of 
the carboxylic acids on the surface (d a ) expressed in number per 
nm 2 was calculated using the equation:
 da =
mola×NA
N P×SA
 
where mol a is the calculated mol of acid, N A is Avogadro’s 
number, NP is the number of nanoparticles in sample (calculated 
from the density provided by the manufacturer and corrected for 
dilution) and SA is particle surface area, expressed in nm 2 (from 
manufacturer’s specifi cation). 
 The mean diameter and size distribution of nanoparticles 
(unmodifi ed and vitamin B 12 -conjugated) was determined by 
dynamic light scattering (DLS) using a Viscotek 802 system (Mal-
vern Instruments). Size analysis was carried out on nanoparticles 
suspended in HBSS at pH 7.4 (biological buffer used in cell experi-
ments). The results represent the mean of ten measurements at 
25  ° C. Nanoparticle zeta potential (suspended in HBSS, pH 7.4) 
was measured using a Zetasizer Nano ZS (Malvern Instruments). 
 5.4. Cell Culture 
 Caco-2 cells were obtained from the European Cell Culture Collec-
tion and used between passages 46–59. Cells were grown to con-
fl uence in 75 cm 2 fl asks (canted neck and vented caps, Corning) 
in Eagle’s Minimum Essential Medium (EMEM), supplemented 
with 10% foetal bovine serum, antibiotics and antimycotics, 
L-glutamine and non-essential amino acids. Upon confl uence, 
cells were detached from the fl asks and seeded on permeable 
supports (Transwell, Corning, 12 mm diameter, 1.1 cm 2 , 0.4  µ m 
pore size). Transepithelial Electrical Resistance (TEER, Ωcm 2 ) was 
measured using a portable epithelial voltohmmeter (EVOM, World 
Precision Instruments) and cell monolayers with TEER exceeding 
1000 Ωcm 2 on day 21 of culture were deemed suitable for 
experiments. 
 5.5. Cell Uptake and Transport Studies 
 Culture medium was replaced with Hank’s Balanced Salt Solution 
(HBSS), buffered with 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid (HEPES, 20 mM) and cell monolayers incubated for 45 min. 
Unmodifi ed YO nanoparticles (50, 100, 200 nm) and vitamin 
B 12 -conjugated nanoparticles were suspended in HBSS/HEPES 
buffer to achieve a fi nal nanoparticle concentration of 400  µ g/
mL. 3  µ g of recombinant human intrinsic factor (rHUIF, Autogen 
Bioclear Ltd) was added per 1 mL of 400  µ g/mL suspension of 
B 12 -conjugated nanoparticles. This amounted to 7.13  × 10 
2 , 
1.44  × 10 3 and 2.87  × 10 3 molecules of IF per 1  µ m 2 surface area 
of 50, 100, and 200 nm nanoparticles, respectively. The solution 
was incubated at 37  ° C prior to application to cells. Nanoparticle 
suspensions (0.5 mL) were applied to the apical chamber of trip-
licate wells and the Caco-2 cultures incubated at 37  ° C over 3 h. 
At 30 min sampling intervals, 100  µ L of the medium was removed 
from the basolateral side and fl uorescence intensities were 
recorded. Sample losses were replaced with 100  µ L of HEPES/
HBSS. Cell uptake of nanoparticles was determined by measuring 
the supernatant fl uorescence following cell lysis using 0.2% v/v 
Triton X-100 (Fluka) (10 min incubation) and centrifugation (to 
remove cell debris). Cell uptake and transport of nanoparticles was 
quantifi ed by fl uorescence (Dynex microplate reader, 529 nm/546 
nm) using appropriate calibration curves for unmodifi ed and con-
jugated nanoparticles. 
 The effect of soluble ligand competition on cell uptake of 
nanoparticles was assessed in the presence of excess cyanoco-
balamin (500  µ g per 0.5 mL suspension of vitamin B 12 -conju-
gated nanoparticles). Soluble vitamin B 12 transport studies were 
conducted in a similar manner to nanoparticle transport experi-
ments, with vitamin B 12 applied to the cells at 1 mg/mL and quan-
tifi ed by UV absorbance (350 nm, Beckman Coulter DU 800 UV 
spectrophotometer). 
 5.6. Immunostaining for Cubilin Receptor, Clathrin 
and Caveolin-1 
 For immunostaining experiments, culture medium was removed 
and the cells (as polarized monolayers) fi xed with 4% w/v para-
formaldehyde (diluted in PBS) for 10 min at room temperature. 
For clathrin and caveolin-1 staining, an additional permeabi-
lization step was conducted via the addition of 0.2% v/v Triton 
X-100 for 10 min. The cells were washed with PBS before incuba-
tion with 1% w/v BSA (in PBS; for 1 h). The primary antibodies 
for cubilin receptor and caveolin-1 (cubilin H-300; caveolin-1 
H-97; rabbit, anti-human; Santa Cruz Biotechnology, Inc.) were 
diluted 1:50 with 1% BSA/PBS and incubated with the cells for 
30 min. For clathrin immunostaining, the rabbit, anti-clathrin 
primary antibody (Abcam) was diluted 1:200 in 1% BSA/PBS. 
The cells were washed 3 times with PBS and incubated with the 
secondary antibody (goat, anti-rabbit IgG-rhodamine and goat, 
anti-rabbit IgG-FITC for cubilin/caveolin-1 and clathrin, respec-
tively) diluted 1:100 (in 1% BSA/PBS) for another 30 min. The 
control cell layers were incubated with the appropriate secondary 
antibody only. Following a fi nal wash step, the cell nuclei were 
stained with Hoechst 33342 (0.1 mg/mL), the cells washed and 
the fi lter membrane excised from the insert. Cells were mounted 
on a slide using 1,4-diazabicyclo[2.2.2]octane (DABCO) (1% 
diluted in 9:1 glycerol:PBS) and covered with a glass cover slip. 
Confocal images were taken using a Leica SP2 CLSM-Micro4 con-
focal microscope. 
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 5.7. Imaging of Nanoparticle Uptake and Lysosomal Staining 
 Caco-2 cells were cultured as polarized monolayers in the manner 
described above. Lysotracker Green DND-26 (Invitrogen) was 
diluted according to the manufacturer’s instructions in HBSS and 
nanoparticles (unmodifi ed or B 12 -conjugated) were suspended 
in this solution to achieve a fi nal nanoparticle concentration of 
250  µ g/mL. The suspension was incubated with IF prior to applica-
tion to the cell, as described above. Lysotracker-containing nano-
particle suspension (0.5 mL) was applied to the apical side of the 
cell monolayers and cells incubated at 37  ° C for 2 h. For anti-LAMP1 
(lysosomal-associated membrane protein 1) immunostaining 
studies, nanoparticles (unmodifi ed or B 12 -conjugated) were applied 
(in HEPES-buffered HBSS) to the apical side and the cells incubated 
at 37  ° C over 2 h. Following removal of the nanoparticle suspen-
sion and cell monolayer washing, the cells were then fi xed with 4% 
paraformaldehyde. Cells were then permeabilized with 0.2% Triton 
X-100 over 10 min and after another wash step, incubated in 1% 
BSA/PBS at 4  ° C for 1 h before the addition of anti-LAMP1 antibody 
(Sigma-Aldrich), diluted 1:50 in 1% BSA/PBS for 30 min. The cells 
were washed with PBS and incubated with the secondary antibody 
[goat, anti-rabbit IgG-FITC (Sigma-Aldrich)] diluted 1:100 (in 1% 
BSA/PBS) for another 30 min (whilst protecting from light). Fol-
lowing a fi nal wash step, cells were stained for nuclei, followed by 
sample mounting on glass slides. Sample imaging was conducted 
by confocal microscopy, as detailed above. 
 Confocal imaging was conducted using a sequential scanning 
mode, where cross-emission between different fl uorophores is mini-
mized. However, a control set of experiments were conducted to verify 
that the imaged pattern did not result from fl uorophore cross-emis-
sion between the Lysotracker marker and fl uorescent nanoparticles. 
In these experiments, cell samples incubated with the Lysotracker 
probe were imaged using YO nanoparticle scan settings (529 
nm/546 nm, excitation/emission), whilst cells treated with YO nano-
particles were visualized using Lysotracker scan settings (504 nm/511 nm 
excitation/emission) (Supporting Information, Figure S9). 
 5.8. Clathrin and Caveolae Inhibition Studies 
 Caco-2 cell monolayers were treated with inhibitors of specifi c 
endocytic pathways, genistein (200  µ M), fi lipin (5  µ g/mL) or chlor-
promazine (10  µ g/mL), diluted in HBSS/HEPES for 1 h at 37 ° C 
prior to the addition of nanoparticles. [ 21 ] Unmodifi ed and vitamin 
B 12 -conjugated nanoparticles (in the presence of IF) were applied 
to the cells suspended in HBSS/HEPES (400  µ g/mL) containing 
one of the above inhibitors for 3 h. At 30 min intervals, 100  µ L 
samples were removed from the basolateral side for fl uorescence 
determination in order to quantify nanoparticle transport across 
the cell monolayers. At the fi nal sampling time point, nanoparticle 
internalization was determined following cell lysis, as described 
above. For the potassium depletion study, conducted to perturb 
clathrin-mediated endocytosis, [ 21 , 69 ] Caco-2 cells were washed 
once with potassium-free buffer (pH 7.4), containing 140 mM 
NaCl (BDH, Analar), 20 mM HEPES, 1 mM CaCl 2 , 1 mM MgCl 2 and 
1 mg/mL D-glucose (GIBCO), followed by a wash with a hypotonic 
buffer (potassium free buffer diluted 1:1 with water). The cells 
were then washed again twice with potassium free buffer. Control 
wells were treated with buffer (pH 7.4), containing 140 mM NaCl, 
20 mM HEPES, 1 mM CaCl 2 , 1 mM MgCl 2 , 1 mg/mL D-glucose and 
10 mM KCl. Vitamin B 12 -conjugated nanoparticles were incubated 
with the cells in potassium-free or potassium-containing buffer as 
indicated. Subsequently, nanoparticle uptake and transport was 
determined by fl uorescence. 
 As a control for clathrin-mediated uptake, [ 21 ] FITC-transferrin 
(Autogen Bioclear LTD, diluted in HBSS to a fi nal incubation con-
centration of 100  µ g/mL) was applied to the apical chambers in the 
presence or absence of chlorpromazine (10  µ g/mL), a specifi c inhib-
itor of clathrin-mediated endocytosis. In addition, native cyanoco-
balamin (vitamin B 12 ) was also applied in the presence of IF and in 
conjunction with the same inhibitor, to confi rm the route of inter-
nalization of the soluble ligand and cell uptake and transport was 
determined via UV-absorbance at 350 nm. To assess the specifi city 
of fi lipin as an inhibitor of caveolae-mediated uptake, [ 40 , 70 ] trans-
port of Alexa Fluor 488-labelled cholera toxin subunit B (Invitrogen, 
applied at 5  µ g/mL) was determined following its application with or 
without fi lipin (5  µ g/mL) (Supporting Information, Figure S10). 
 5.9. Statistical Analysis 
 All experiments were carried out using triplicate samples. One 
way analysis of variance (ANOVA) followed by Bonferroni post-hoc 
test was applied for comparison of group means of three or more 
groups, whilst Student’s t-test was used for comparison of two 
groups. P values of  < 0.05 were considered statistically signifi cant. 
 ∗ ,  ∗ ∗ ,  ∗ ∗ ∗ and  ∗ ∗ ∗ ∗ indicate p  < 0.05, p  < 0.01, p  < 0.001 and p  < 
0.0001, respectively, whilst ‘ns’ indicates non-signifi cant. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library 
or from the author. It includes characterization of the vitamin 
B 12 derivative (by means of NMR, MS and HPLC), fl uorescence 
quenching experiments showing B 12 -conjugation to nanoparticle 
surface, particle potentiometric titration experiments, nanoparticle 
size and zeta potential analyses, confocal cross-emission control 
experiments, cellular uptake and transport of FITC-transferrin and 
cholera toxin B-subunit and unmodifi ed nanoparticles in the pres-
ence of clathrin- and caveolae-specifi c inhibitors. 
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